Nearly 100 biotechs went public amid the industry’s IPO frenzy in 2021, driven by an influx of pandemic-driven investments. But many of those companies have little to show investors.
2021 Sparked a Banner Year for Biotech IPOs. Where Are They Now? Read More »
U.S. President Donald Trump signed a spending package into law Tuesday that reauthorizes the FDA’s previously stalled rare pediatric disease priority review voucher program, among other initiatives, while ending a three-day partial government shutdown.
Abbott needs to conduct more performance testing to ensure its FreeStyle Libre devices are accurate, FDA inspectors found.
Abbott receives FDA warning letter over Freestyle Libre CGMs Read More »
Novo Nordisk beat analyst expectations for the fourth quarter, but the result was overshadowed by softened expectations for this year.
Novo Slides 14% as Early Q4 Results Predict Sales Decline for 2026 Read More »
Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.
Pfizer’s Early Metsera Data Leaves Analysts Wanting More Read More »
The full financial impact of the price hikes could exceed $67 million each year in two dozen markets, according to the new study published in Health Affairs.
Prices rise at surgery centers acquired by Optum: study Read More »
Proteger tu equipo de cómputo durante traslados diarios requiere más que una simple bolsa. Las mochilas para laptop se han convertido en herramientas esenciales para profesionales y estudiantes que buscan combinar seguridad, funcionalidad y diseño en un solo accesorio. La elecci …
Agent Assist, developed with Google Cloud, summarizes conversations between workers and beneficiaries while highlighting relevant information, like enrollees’ benefit and eligibility details.
Humana rolls out AI support tool for call centers Read More »
The purchase will give Medtronic a larger presence in the cath lab, with a tool to help diagnose and treat coronary artery disease.
In its 2025 full year and fourth-quarter earnings call, Merck executives touted the merits of recent deals and what CEO Robert Davis called “probably the broadest and widest pipeline we’ve had in years.”
Merck Bats Away ‘Modest Growth’ Accusations, Touts Broad Pipeline Read More »
